- Home
- HTCR vs VYNE Comparison
HTCR vs VYNE Comparison
Compare HTCR & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HTCR | VYNE |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 12.5M |
| IPO Year | 2022 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HTCR | VYNE |
|---|---|---|
| Price | $0.43 | $0.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 193.6K | ★ 870.3K |
| Earning Date | 11-18-2025 | 11-06-2025 |
| Dividend Yield | ★ 29.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $16,189,136.00 | $524,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | $16.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.29 |
| 52 Week Low | $0.39 | $0.28 |
| 52 Week High | $3.38 | $4.30 |
Technical Indicators
Market Signals| Indicator | HTCR | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 53.05 |
| Support Level | $0.42 | $0.37 |
| Resistance Level | $0.48 | $0.39 |
| Average True Range (ATR) | 0.04 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 13.40 | 58.97 |
Price Performance
Historical ComparisonAbout HTCR Heartcore Enterprises Inc.
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.